Aditxt (NASDAQ:ADTX) Major Shareholder Financial Lp Hrt Sells 5,120,480 Shares of Stock

Aditxt, Inc. (NASDAQ:ADTX) major shareholder Financial Lp Hrt sold 5,120,480 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $0.02, for a total value of $102,409.60. Following the completion of the transaction, the insider directly owned 2,406,438 shares in the company, valued at $48,128.76. The trade was a 68.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 18th, Financial Lp Hrt bought 7,340,178 shares of Aditxt stock. The shares were bought at an average cost of $0.01 per share, with a total value of $73,401.78.
• On Tuesday, June 16th, Financial Lp Hrt sold 3,132,480 shares of Aditxt stock. The shares were sold at an average price of $0.01, for a total value of $31,324.80.
• On Friday, June 12th, Financial Lp Hrt purchased 4,252,767 shares of Aditxt stock. The stock was purchased at an average cost of $0.02 per share, for a total transaction of $85,055.34.
• On Friday, June 5th, Financial Lp Hrt sold 735,462 shares of Aditxt stock. The stock was sold at an average price of $0.06, for a total transaction of $44,127.72.
• On Thursday, June 4th, Financial Lp Hrt acquired 843,622 shares of Aditxt stock. The shares were purchased at an average cost of $0.08 per share, with a total value of $67,489.76.
• On Friday, April 24th, Financial Lp Hrt sold 1,089 shares of Aditxt stock. The stock was sold at an average price of $7.56, for a total transaction of $8,232.84.
• On Thursday, April 23rd, Financial Lp Hrt sold 141 shares of Aditxt stock. The shares were sold at an average price of $7.83, for a total transaction of $1,104.03.
• On Tuesday, April 21st, Financial Lp Hrt bought 2,700 shares of Aditxt stock. The stock was purchased at an average price of $8.91 per share, for a total transaction of $24,057.00.
• On Wednesday, April 22nd, Financial Lp Hrt sold 443 shares of Aditxt stock. The shares were sold at an average price of $8.10, for a total transaction of $3,588.30.

Aditxt Stock Performance

Shares of NASDAQ:ADTX traded down $0.03 during midday trading on Wednesday, hitting $0.01. The company’s stock had a trading volume of 4,650,711,153 shares, compared to its average volume of 124,214,039. The stock’s 50 day simple moving average is $3.16 and its 200 day simple moving average is $113.78. The stock has a market capitalization of $7,929.40, a price-to-earnings ratio of -0.00 and a beta of 0.84. Aditxt, Inc. has a fifty-two week low of $0.00 and a fifty-two week high of $53,451.08.

Aditxt (NASDAQ:ADTX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $315,563.31 earnings per share for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Analyst Ratings Changes

ADTX has been the topic of several research reports. Wall Street Zen upgraded shares of Aditxt to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Aditxt in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Aditxt

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.